Takeda Pharmaceutical (NYSE:TAK) Downgraded to Buy Rating by Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

A number of other brokerages have also commented on TAK. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an “overweight” rating on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $17.84 on Friday. The business has a 50 day moving average of $17.65 and a 200-day moving average of $15.66. The company has a market capitalization of $56.75 billion, a P/E ratio of 74.32 and a beta of 0.01. Takeda Pharmaceutical has a 1 year low of $12.99 and a 1 year high of $18.82. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 29th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.55 by $0.40. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The business had revenue of $6.75 billion for the quarter, compared to the consensus estimate of $7.81 billion. On average, equities research analysts predict that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Large investors have recently modified their holdings of the company. Private Trust Co. NA lifted its holdings in Takeda Pharmaceutical by 84.7% in the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares during the period. Twin Peaks Wealth Advisors LLC acquired a new stake in Takeda Pharmaceutical during the 2nd quarter worth about $28,000. Evelyn Partners Investment Management LLP raised its position in shares of Takeda Pharmaceutical by 163.4% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock worth $39,000 after acquiring an additional 1,560 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after acquiring an additional 1,684 shares in the last quarter. Finally, SHP Wealth Management acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at about $42,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.